Tofacitinib ^[*]

 

 Buy Article Permissions and Reprints

^* Dieser Artikel ist zuerst erschienen in Dtsch Med Wochenschr 2014; 139: 1003–1008.

• Literatur

• 1 Baker SJ, Rane SG, Reddy EP. Hematopoietic cytokine receptor signaling. Oncogene 2007; 26: 6724-6737
  CrossrefPubMedGoogle Scholar
• 2 Burmester GR, Blanco R, Charles-Schoeman C et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet 2013; 381: 451-460
  CrossrefPubMedGoogle Scholar
• 3 Changelian PS, Flanagan ME, Ball DJ et al. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 2003; 302: 875-878
  CrossrefPubMedGoogle Scholar
• 4 Cohen S, Zwillich SH, Chow V et al. Co-administration of the JAK inhibitor CP-690,550 and methotrexate is well tolerated in patients with rheumatoid arthritis without need for dose adjustment. Br J Clin Pharmacol 2009; 69: 143-151
  PubMedGoogle Scholar
• 5 EMA/248755/2013 Refusal of the marketing authorisation for Xeljanz (tofacitinib). 2013 http://www.ema.europa.eu/ema/pages/includes/document/open_document.jsp?webContentId=WC500142485 [cited 2013 September 11]
  PubMedGoogle Scholar
• 6 EULAR. Updated EULAR Recommendations on Management of Rheumatoid Arthritis (RA). 2013 www.eular.org/myUploadData/files/EULAR%20RA%20recommendations%20FINAL.pdf [cited 2013 September 11]
  PubMedGoogle Scholar
• 7 FDA. FDA News Release: FDA approves Xeljanz for rheumatoid arthritis. 2012 http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm327152.htm [cited 2013 September 11]
  PubMedGoogle Scholar
• 8 Felson DT, Anderson JJ, Boers M et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 727-735
  CrossrefPubMedGoogle Scholar
• 9 Fleischmann R, Kremer J, Cush J et al. Plazebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 2012; 367: 495-507
  CrossrefPubMedGoogle Scholar
• 10 Fox DA. Kinase inhibition-a new approach to the treatment of rheumatoid arthritis. N Engl J Med 2012; 367: 565-567
  CrossrefPubMedGoogle Scholar
• 11 Fransen J, van Riel PL. The Disease Activity Score and the EULAR response criteria. Clin Exp Rheumatol 2005; 23: S93-S99
  PubMedGoogle Scholar
• 12 Fries JF, Spitz P, Kraines RG et al. Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23: 137-145
  CrossrefPubMedGoogle Scholar
• 13 Gupta P, Alvey C, Wang R et al. Lack of effect of tofacitinib (CP-690,550) on the pharmacokinetics of the CYP3A4 substrate midazolam in healthy volunteers: confirmation of in vitro data. Br J Clin Pharmacol 2012; 74: 109-115
  CrossrefPubMedGoogle Scholar
• 14 Johnston JA, Kawamura M, Kirken RA et al. Phosphorylation and activation of the Jak-3 Janus kinase in response to interleukin-2. Nature 1994; 370: 151-153
  CrossrefPubMedGoogle Scholar
• 15 Kremer J, Li Z, Hall S et al. Tofacitinib (CP-690,550), an oral JAK Inhibitor, in combination with traditional DMARDs: Phase 3 study in Patients with active Rheumatoid Arthritis with inadequate response to DMARDs. Ann Rheum Dis 2011; 70: 170
  PubMedGoogle Scholar
• 16 Kudlacz E, Perry B, Sawyer P et al. The novel JAK-3 inhibitor CP-690550 is a potent immunosuppressive agent in various murine models. Am J Transplant 2004; 4: 51-57
  PubMedGoogle Scholar
• 17 McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011; 365: 2205-2219
  CrossrefPubMedGoogle Scholar
• 18 Meyer DM, Jesson MI, Li X et al. Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis. J Inflamm (Lond) 2010; 7: 41
  CrossrefPubMedGoogle Scholar
• 19 Milici AJ, Kudlacz EM, Audoly L et al. Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis. Arthritis Res Ther 2008; 10: R14
  CrossrefPubMedGoogle Scholar
• 20 Musso T, Johnston JA, Linnekin D et al. Regulation of JAK3 expression in human monocytes: phosphorylation in response to interleukins 2, 4, and 7. J Exp Med 1995; 181: 1425-1431
  CrossrefPubMedGoogle Scholar
• 21 O'Shea JJ, Pesu M, Borie DC et al. A new modality for immunosuppression: targeting the JAK/STAT pathway. Nat Rev Drug Discov 2004; 3: 555-564
  CrossrefPubMedGoogle Scholar
• 22 Ory PA. Interpreting radiographic data in rheumatoid arthritis. Ann Rheum Dis 2003; 62: 597-604
  CrossrefPubMedGoogle Scholar
• 23 Pfizer. Tofacitinib for Treatment of Rheumatoid Arthritis (NDA 203214)Advisory Meeting. 2012 http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ArthritisAdvisoryCommittee/UCM302960.pdf [cited 2013 September 11]
  PubMedGoogle Scholar
• 24 Pfizer. Xeljanz^® (Tofacitinib), Prescribing Information. 2012 http://www.xeljanz.com or http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203214Orig1s000TOC.cfm [cited 2013 September 11]
  PubMedGoogle Scholar
• 25 Riese RJ, Krishnaswami S, Kremer J. Inhibition of JAK kinases in patients with rheumatoid arthritis: scientific rationale and clinical outcomes. Best Pract Res Clin Rheumatol 2010; 24: 513-526
  CrossrefPubMedGoogle Scholar
• 26 Schneider M, Lelgemann M, Abholz H-H et al. Interdisziplinäre Leitlinie: Management der frühen rheumatoiden Arthritis. 3^rd: Edition ed Berlin, Heidelberg, New York: Springer Verlag; 2011
  Google Scholar
• 27 Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet 2010; 376: 1094-1108
  CrossrefPubMedGoogle Scholar
• 28 Sharp JT, Lidsky MD, Collins LC et al. Methods of scoring the progression of radiologic changes in rheumatoid arthritis. Correlation of radiologic, clinical and laboratory abnormalities. Arthritis Rheum 1971; 14: 706-720
  CrossrefPubMedGoogle Scholar
• 29 Smolen JS, Steiner G. Therapeutic strategies for rheumatoid arthritis. Nat Rev Drug Discov 2003; 2: 473-488
  CrossrefPubMedGoogle Scholar
• 30 van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol 2000; 27: 261-263
  PubMedGoogle Scholar
• 31 van der Heijde D, Tanaka Y, Fleischmann R et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum 2013; 65: 559-570
  CrossrefPubMedGoogle Scholar
• 32 van Vollenhoven RF, Fleischmann R, Cohen S et al. Tofacitinib or adalimumab versus Plazebo in rheumatoid arthritis. N Engl J Med 2012; 367: 508-519
  CrossrefPubMedGoogle Scholar
• 33 van Vollenhoven RF. Treatment of rheumatoid arthritis: state of the art 2009. Nat Rev Rheumatol 2009; 5: 531-541
  CrossrefPubMedGoogle Scholar
• 34 Vijayakrishnan L, Venkataramanan R, Gulati P. Treating inflammation with the Janus kinase inhibitor CP-690,550. Trends Pharmacol Sci 2011; 32: 25-34
  CrossrefPubMedGoogle Scholar
• 35 Witthuhn BA, Silvennoinen O, Miura O et al. Involvement of the Jak-3 Janus kinase in signalling by interleukins 2 and 4 in lymphoid and myeloid cells. Nature 1994; 370: 153-157
  CrossrefPubMedGoogle Scholar

• Supplementary Material